AG-13958

AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) [1].

Product Specifications

CAS Number

[319460-94-1]

Product Name Alternative

AG-013958

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ag-13958.html

Concentration

10mM

Purity

99.71

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC(C)=NN1C)NC2=CC(NC3=CC4=C(C=C3)C(/C=C/C5=NC=CC=C5)=NN4)=CC=C2F

Molecular Formula

C26H22FN7O

Molecular Weight

467.50

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]M.B. Kosa, et al. Ocular and Systemic Pharmacokinetics of AG-013958 With Sub-Tenon Administration To Cynomologus Monkeys. Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5379.|[2]Solowiej J, et al. Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain. ACS Chem Biol. 2013 May 17;8 (5) :978-86.